Neuroinflammation and activation of innate immunity are early events in neurodegenerative diseases including Alzheimer's disease (AD). Recently, a rare mutation (R47H) in the gene Triggering receptor expressed on myeloid cells 2 (TREM2) has been associated with a substantial increase in the risk of developing late onset Alzheimer's disease. To uncover the molecular mechanisms underlying this association we investigated the RNA and protein expression of TREM2 in APP/PS1 transgenic mouse brain (APP/PS1-tg2576).
Neuroprotective effect of TREM-2 in ageing and
Neuroinflammation and activation of innate immunity are early events in neurodegenerative diseases including Alzheimer's disease (AD). Recently, a rare mutation (R47H) in the gene Triggering receptor expressed on myeloid cells 2 (TREM2) has been associated with a substantial increase in the risk of developing late onset Alzheimer's disease. To uncover the molecular mechanisms underlying this association we investigated the RNA and protein expression of TREM2 in APP/PS1 transgenic mouse brain (APP/PS1-tg2576).
Our findings suggest that TREM2 not only plays a critical role in the inflammation, also plays a role in neuronal cell survival and in neurogenesis. We have shown that TREM2 is a soluble protein transported by macrophages through ventricle walls and choroid plexus then enters in the brain parenchyma via radial glial cells. TREM2
protein is essential for neuroplasticity and myelination. Later in life lack of TREM2 protein may accelerate ageing processes and neuronal cell loss and reduce microglial activity, ultimately that leads to neuroinflammation. As inflammation plays a major
Introduction
The immune system has evolved to defend against pathogens and clear up endogenous defective cells (plaques/dying neurons), it is thus conceivable that the immune system may be actively be involved in Alzheimer' disease (AD) Huntington's disease [6] , amyotrophic lateral sclerosis (ALS) [7] , and multiple sclerosis [8] . There is a highly organized innate immune response during the early stages of inflammation. This inflammatory response is characterized by the expression of various immunological proteins in the circumventricular organs (CVOs), choroid plexus (CPs) and other structures lacking the protection conferred by the blood-brain barrier (BBB) [9, 10] . The response extends progressively to affect microglia and macrophages across the brain parenchyma and may lead to the onset of an adaptive immune response [11, 12] .
Alzheimer's diseases (AD) is characterized by the presence of extracellular amyloid deposits comprised of aggregated β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles containing hyperphosphorylated, aggregated tau protein [13, 14] . The deposition of Aβ in brain areas involved in cognitive functions is assumed to initiate a pathological cascade that ultimately results in inflammation, synaptic dysfunction, synaptic loss and neuronal death [15, 16] .
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia/macrophage receptor that acts as a sensor for a wide array of lipids including apolipoprotein (ApoE) and Phospholipid transfer protein (PLTP) [17] [18] [19] [20] .
Recent genome-wide association studies have shown that a rare mutation (R47H) of TREM2 gene is associated with a substantial increase in the risk of developing AD [19] [20] [21] [22] . The absence of TREM2 expression on microglia impairs their capacity to phagocytose cell membrane debris and increases their production of pro-inflammatory cytokines [23, 24] . Identification of this novel variant in the gene encoding for TREM2 has refocused attention onto inflammation as a major contributing factor in AD [25, 26] . DNAX-activating protein of 12kDa (DAP12, also called TYROBP) is a type I transmembrane adapter proteins which associates with the cytosolic portion of TREM2, forming a molecular complex [17, 27] . It is expressed in neurons, microglia and resident macrophages in the CNS [28] and functions to stimulate phagocytosis and to suppress cytokine production and inflammation [29] . Developmental dysregulation of either TREM2 or DAP12 mutation causes an early onset form of dementia with cystic bone disorder, known as Nasu-Hakola disease [30] [31] [32] .
Several mouse models that mimic some of the neuropathological and behavioral features of AD have been developed [33] [34] [35] [36] . Transgenic mice expressing human APP695 containing the double mutation Lys670-Asn, Met 671 Leu (Swedish mutation) and one PS1 mutation (M146V) in tg2576 (APP/PS1-tg2576) displays agedependent increases in Aβ plaques, activated microglia, and astrocytes and dystrophic neuritis [10, 16, 35, 37] . The effects of TREM2 in an AD mouse models, particularly those upon Aβ plaque load, have been studied in different transgenic mouse models, generating conflicting results; one group reported that the absence of TREM2 decreased Aβ load [38] whereas another group reported that TREM2 deficiency increased Aβ deposit in another AD (5xFAD) mouse model [39] . Both groups showed the presence of TREM2 in the microglia or in the peripheral macrophages.
However, none of these papers have mentioned of the TREM2 protein expression in the neurons or other glial cells (e.g. in astrocytes or oligodendrocytes). 
Materials and methods

Transgenic mice
Transgenic mice over expressing the 695-amino acid isoform of human Alzheimer β-amyloid (Aβ) precursor protein containing a Lys 670 → Asn, Met 671 → Leu mutation (K670N and V717F, Swedish mutation) and one PS1 mutation (M146V), driven by Thy1 promoter on a C57BL/6 genetic background (Tg2576) were purchased from Jackson Laboratory, USA. Neuropathological characterisation of these animals has previously been described in detail [10, 35] . At 3-4 months, these mice start accumulating amyloid deposition and plaques formation, by 9-12 months they resemble a more severe stage of AD pathology [10] . All animals were housed under standard conditions (12h light-dark cycle, 20˚C ambient temperature) with free access to food and water. All procedures were performed under license in accordance to the UK Animals (Scientific Procedures) Act 1986.
Six mice per age group (3, 6, 9 and 10-12 months-old) were used for RT-PCR, immunohistochemistry. Similarly, six mice from each group used for protein quantitation by Western blotting (WB), described subsequently. C57/BL mice were used as control samples (n=6, age-matched to APP-PS1 mice).
Tissue preparation
Mice were terminally anaesthetized with carbon dioxide and culled. Unfixed tissues were dissected from various brain regions from control and APP-PS1 mouse brains and snap frozen in dry ice until analyzed by either RT-PCR or Western blotting as described previously [40] . For histochemical analyses, animals were anesthetized with pento-barbitone and flash-perfused transcardially with 0.9% saline followed with 4%
(v/v) paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). Brains were sectioned by microtome as described previously [41] . Free-floating sections were prepared (25µm coronal sections in 0.1 M PBS) through the entire olfactory bulb, hippocampus, cortex, mid brain and cerebellum. Sections were then stained by immunohistochemistry as described below.
RNA isolation and RT-PCR
For RNA analysis mouse brain (n = 6) tissues were dissected from frontal cortex (that also contains blood vessels and endothelium) as described above. AGCCTTCTCCATGGTGGTGAAGAC, product size 500 bp). PCR products were separated on 1.5 % agarose gels and photographed under UV illumination.
In situ hybridisation (ISH)
Brain tissues were prepared for in situ hybridization and probed as described previously [40] .
Synthesis of DIG labelled probes for ISH
To synthesize digoxigenin (DIG)-labeled RNA probes, the target TREM2 cDNA was amplified by PCR using primers designed on the basis of the mouse TREM2 cDNA sequence used in RT-PCR. The primers used for DIG labeling were (TREM2-insF: TAATACGACTCACTATAGG GCTGCTGATCACAGCCCTG and TREM2-insR: ATTTAGGTGACACTATAGAGGCATAGAGTGGGCTCATCTG).
The PCR product was amplified using a 5′ primer containing a T7 phage promoter sequence and a 3′ primer containing an SP6 phage promoter sequence, generating a template for transcription of a sense and an antisense probe, respectively. The PCR products (470 bp) were sequenced and homology checked by BLAST search (NCBI database). In vitro transcription reactions were performed using dig-UTP RNA labeling mix (Roche, Mannheim, Germany) and SP6 or T7 RNA polymerase (Roche).
ISH with DIG labelled probe
Brain, liver and other sections were fixed in 4% PFA for 10 min, permeabilized for 10 min in PBS with 0.5% Triton X-100 and acetylated by 10 min incubation in a solution made of 250 ml of water with 3.5 ml of triethanolamine and 625 µl of acetic anhydride added drop wise [40] . Pre-hybridization was performed in hybridization buffer made of 50% formamide, 5 × SSC and 2% blocking reagent (Roche) for 3 hours at 62°C. Hybridization with DIG-labeled probes (100 ng/ml) was performed in the same buffer overnight at 62°C. Stringency washing was performed in 0. and sections mounted in PBS-glycerol and a coverslips applied. Non-specific binding was analysed using sense probes (data not shown).
Sources of antibodies
The following primary antibodies were raised again mouse TREM2 peptides, goat polyclonal (PAB) anti-TREM2 (ab95470) or rabbit polyclonal anti-TREM2
(ab175525) and for human cell line mouse monoclonal (Ab201621). Other antibodies used include anti-TREM2 (HPA010917, Sigma-Aldrich), rabbit PAB synaptophysin, rabbit PAB synapsin (from Abcam, Cambridge, UK). The monoclonal anti-aβ antibodies (6E10) (Signet laboratory) had been described previously [10] and rabbit anti-aβ (1-40) and CD11b (Millipore), anti-GFAP (Sigma-Aldrich), Iba1 (WAKO)
are described in 
SDS-PAGE and western blotting
Protein lysates were prepared from cortex of mouse brains (n =6 
Immunofluorescence (IF)
Sections were blocked using blocking buffer (0.1 M PBS, 0.1% Triton X100, 10%
normal donkey serum) for 1 h at room temperature, then incubated overnight at 4°C
with primary antibody diluted in blocking buffer. Alexa Fluor-conjugated secondary antibodies were used for detection and samples counterstained with 4′6-diamidino-2-phenylindole (DAPI, Sigma). Sections were then mounted on glass slides with coverslips using FluorSave (Calbiochem).
Primary Rat hippocampal cultures
Cultures of dissociated hippocampal neurons were prepared using previously described methods [42] with some modifications. Hippocampal tissue was collected ice-cold methanol and analyzed by IF staining as above and examined by confocal microscopy. All cell culture media and reagents were purchased from Invitrogen.
Neuronal cell lines
Neuronal cell lines (SKNF1 and SH5SY) were plated on PDL coated glass cover slips (as described above) in 24 wells plate with Dulbecco's modified Eagle's medium (DMEM, Gibco), 10% fetal calf serum and 1% penicillin-streptomycin-fungizone (PSF). After 1-3 days in vitro cells were fixed with 80% ice-cold methanol and analyzed by IF.
Primary rat microglial culture and LPS treatment
The cortices of new-born SD rats (between P1 to P5) were removed, stripped of the meninges and then chopped up with a razor blade and incubated in 0.1% trypsin with PBS and fixed as described above.
Microscopy
Bright field images were taken and quantified using Lucia imaging software and a Leica FW 4000 upright microscope equipped with a SPOT digital camera.
Fluorescence images were obtained using a Leica DM6000 wide field fluorescence microscope equipped with a Leica FX350 camera and x20 and x40 objectives. Images were taken through several z-sections and de-convolved using Leica software. A Leica TCS SP2 confocal laser-scanning microscope was used with x40 and x63
objectives to acquire high-resolution images.
Image and statistics analysis
All experiments were performed in triplicate. Western blot and immunofluorescence images were quantified using ImageJ software (NIH). For Western blots, the gel analyzer module was used. Selected bands were quantified based on their relative intensities, adjusted for background with fold-change in intensity subjected to statistical analysis as described below. Immunofluorescence was quantified using methods previously described [16] . Values in the figures are expressed as mean ± SEM. To determine the statistical significance, values were analyzed by Student's ttest when comparing difference between case (APP-PS1 brain) and controls. A probability value of p<0.05 was considered to be statistically significant.
Results: TREM2 in wild-type mouse brain
As a first step in determining possible roles of TREM2 in the brain, we have investigated the expression of TREM2 and its binding partner DNAX-activating protein of 12kDa (DAP12, also called TYROBP) in wild-type (WT) mouse brain over time. DAP12 is a type I transmembrane adapter proteins which forms a molecular complex with TREM-2 [17, 27] . RT-PCR of TREM2 and DAP12 was performed on tissues from the frontal cortex of 3, 6, 9 and 12 months old WT mice (n = 6 per group). TREM2 levels demonstrated a gradual increase over time in the control mice, peaking at 9 months of age ( Figure 1a ). DAP12, on the other hand, remained consistent over time (Figure 1b) , significantly higher than TREM2 at 3 and 6 months.
These measures indicated that both TREM2 and DAP12 are present in the brain.
To investigate the cellular localization of TREM2 mRNA in situ hybridization experiments were performed using a TREM2 probe (Figure 1g ; [43, 44] and a β-actin probe was used on sections from hippocampus to assess hybridization stringency (Figure 1j ). Given the limited localisation of TREM2 mRNA in brain parenchyma, these data suggest that TREM2 is being derived from elsewhere.
WB analysis of frontal cortex from WT mice (at 3, 6, 9 and 12 months, n= 6 per group) complemented the RT-PCR results, indicating that levels of TREM2 protein Figure   2d ). This finding suggested that TREM2 protein was present in the neurons, in the oligodendrocytes (in WMT), NG2 positive glia whereas absent in the astrocytes.
TREM2 expression in APP mouse brain declined with disease progression
Given the co-localisation of TREM2 and Aβ40 in the cortex, we next analyzed the expression of TREM2 in the APP-PS1 mice. RT-PCR of frontal cortex tissue from 3, 6, 9 and 12 months of age, indicated that TREM2 levels were consistently higher in APP-PS1 mice than controls, significantly so at 3 months and 12 months (p <0.001; Figure 1a ). Curiously there was no significant difference in DAP12 mRNA levels between the two groups of mice at any time point (Figure 1b) . And when we compared TREM2 and DAP12 mRNA in the APP-PS1 brain samples, we noted significantly higher levels of DAP12 at 3 months of age (p <0.0001, Figure 1c ).
GAPDH was used as an internal control (Figure 1d ). When we analyzed at protein levels (via WB), however, we found that TREM2 levels decreased with age and disease progression in the APP-PS1 mice ( In a third neuronal cell line (SH5SY), we observed TREM2 protein present in the growth cones, suggesting that TREM2 may have important role in cellular differentiation ( Figure 6 f-i).
TREM2 protein was localized in the Golgi complex and in early endosomes
As we have noticed TREM2 protein was visible in perinuclear location, duel labeling of TREM2 and Golgi marker (58K-Golgi) was performed in the SKNF1 cell line.
TREM2 was observed to co-localize with 58K-Golgi in the trans-Golgi location, suggesting a function in sorting and packaging proteins for secretion (Figure 6j-l) .
Punctuate TREM2 proteins in the radial glial cells close to the ventricles were observed (Figure 4h ), therefore SKNF1 cells were stained with TREM2 and an early endosome marker EEA1. Duel Immunofluorescence labeling shows that both proteins co-localized in the endosomes (Figure 6m-o) . EEA1 localizes exclusively to early endosomes and has an important role in endosomal trafficking. Our results suggest that TREM2 protein is transported via EEA1 and is a tethering molecule that provides directionality to vesicular transport from the plasma membrane to the early endosomes.
Microglia cultures and responds to LPS treatment
Finally we assessed TREM2 expression in newly proliferative microglia cultures (Figure 7a-c) , and using higher magnification we found TREM2 was visible in the nucleus and perinuclear location but not in the processes and showed limited colocalisation with microglial marker CD11b (Figure 7d-f) . These data provided the foundation for investigating roles of TREM2 in vitro.
Inflammation is an important part of neurodegenerative conditions, like Alzheimer's disease [45] . Thus we began our investigation into TREM2 functions by analysing the association of TREM2 in inflammation. Microglia culture was treated with 100 nM of LPS on culture medium for 4 hours. Post-LPS treatment TREM2 expression was increased in some newly proliferative microglia, while mature microglia lost the perinuclear localisation and limited co-localisation was seen with CD11b (Figure 7g 
Discussion
The association of TREM2 mutations to an increased risk of AD has emphasised the important role played by neuroinflammation in neurodegenerative diseases [19, 20, 46] . Microglia are the only immune cells present in the CNS parenchyma and are the quick responders to environmental changes by playing a critical role in clearing debris and restoring homeostasis in the CNS [47, 48] . With age, the brain undergoes a homeostatic shift and gradually neuroinflammatory changes develop which compromise neuronal function [29, 49] . In the human brain, TREM2 protein is involved in bone homeostasis, phagocytosis and migration [27, 50, 51] .
We have examined TREM2 mRNA levels (by RT-PCR) in APP-PS1 mice and found that TREM2 transcription was age related and increased with age. This could be due to infiltrating macrophages, and such inflammatory changes and have been described in aged APP-PS1 mice which correlate with synaptic function, or it could be due to excessive microglial proliferation due to inflammatory changes in early disease processes [52] . This findings are supported by others published data on TREM2 expression in AD transgenic mice [53] . To identify the cellular location of TREM2 an in-situ hybridisation was performed in C57/BL6 WT mouse brain with DIG labelled TREM2 probe. Surprisingly, very limited cellular expression of TREM2 RNA in the mouse brain was visible only in some cells close to blood vessels in the brain parenchyma and not present in microglia. This could be due to a limited detection level of microglia with DIG labelled probes, however there was a clear signal in the blood/myeloid cells. TREM2 protein expression as measured by Western blotting was also age-dependent in APP-PS1mice and TREM2 protein levels decreased with age.
As we have observed that TREM2 protein is expressed in all precursor cells including in neuronal precursor cells (NPCs) and glial precursor cells (OPCs), it may therefore be involved in cellular proliferation implying that TREM2 deficiency would result in impaired interactions between microglia and plaques as previously reported [54, 55] .
TREM2 expression is important in limiting neuronal toxicity during the early stages of Aβ deposition. Only one published paper has thus far reported that TREM2 protein was present in neurons in human brain close to a blood vessels [28] . We have shown that in young WT mice TREM2 protein was highly expressed in the pyramidal previously [38] .
In young WT mice TREM2 protein was present in neurogenic niches, therefore we grew primary hippocampal neuron culture to show that TREM2 co-localised with synaptophysin (presynaptic protein) and synapsin (synaptic vesicular protein) in the soma, axon and dendrites. We hypothesised that soluble TREM2 protein could be transported through synaptic vesicles may have a role in synaptogenesis or neurogenesis. TREM2 protein was visible in oligodendrocytes, in the white matter tracts in the cortex, in the olfactory bulb and in striatal bundles indicating that TREM2 protein has a role in myelination so a lack of TREM2 function could be involve in demyelination in demyelinating disorders such as Nasu-Hakola disease, multiple sclerosis and amylotropic lateral sclerosis [31, 46] . TREM2 protein was visible in the nucleus and perinuclear area (within the Golgi complex) of all primary cells (OPC and NPCs) and the highest level was seen in growth cone of neurons and oligodendrocytes, further supporting the role of TREM2 in cell proliferation.
In human and mouse neurons and microglia as well as in human cell lines (microglia and glioblastoma), the receptor is mostly localized not at the surface but within the cell: in the perinuclear area in neurons and spread throughout the cytoplasm in microglia and cell lines [56] . The present work has been carried out in neuronal cell line (SKNF1) using immunofluorescence techniques. TREM2 co-localised with the Golgi marker 58K-Golgi, suggesting it may be involved in sorting and packaging of proteins for secretion. It could be involved in the transport of lipids around the cell that when the process was impaired increased the plaques burden in AD. We have seen punctuate TREM2 protein in the radial glial cells close to the ventricles, Therefore we investigated location of TREM2 in endosomes, using a SKNF1 cell line. TREM2 was found to co-localize with an exclusively early endosome marker EEA1. It may present in late endosome too, at present we are investigating role of TREM2 in different endosomal compartment (unpublished findings).
Our results suggest that TREM2 like EEA1 is a tethering molecule that provides directionality to vesicular transport from the plasma membrane to early endosomes.
TREM2 is mostly distributed intracellular in two pools: a deposit in the Golgi complex and a population in endo/exocytic vesicles that are continuously translocated to, and recycled from the cell surface as reported previously in a microglia cell line 
Conclusion:
We have shown that TREM2 is a serum protein transported by macrophages through ventricle walls, CVO and blood vessels entering the brain parenchyma via radial glial cells. TREM2 protein is essential for neuroplasticity, neurotrophism and myelination.
Later in life a lack of TREM2 protein may accelerate the ageing process and neuronal cell loss. In all ageing diseases TREM2 levels declined and lack of TREM2 reduced microglial activity leading to neuro-inflammation. As inflammation plays a major role in neurodegenerative diseases, a lack of TREM2 could be the missing link between immunomodulation and neuroprotection. 
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